IntelliTraQ – New Web-Based Longitudinal Patient Tracking Tool
Waltham, Mass. (Sept. 25, 2007) — IntrinsiQ, LLC, the leading provider of U.S. oncology market data and business analytics to pharmaceutical, biotechnology and financial companies today launched IntelliTraQ®, the industry’s most comprehensive Web-based survey tool for cancer drug usage.
IntelliTraQ expands the reach and flexibility of IntrinsiQ’s flagship product, IntelliDose®, the largest data tracking resource for oncologists nationwide. IntrinsiQ currently gathers data regarding the treatment of more than 18,500 patients per month.
IntrinsiQ is the only source for automated longitudinal data on trends in cancer drug usage and is relied on by 27 of the 30 largest oncology companies.
The accessibility of this Web-based data collection expands the potential sample size by hundreds of additional practitioners. IntelliTraQ’s flexibility and analytics gives pharmaceutical marketers new insight into emerging trends and patterns of usage. It delivers:
IntelliDose answers the critical question: “What is happening?” IntelliTraQ brings insight to the next level, by seeking to answer the follow-on question: “Why is this happening?”
“IntrinsiQ is the gold standard in U.S. oncology tracking today,” said Jeff Forringer, general manager of the IntrinsiQ Pharmaceutical Data Division. “We provide historic perspective and trend analysis on more than 7 million drug administrations – no one else comes close. The convenience and flexibility of IntelliTraQ will make it even easier for oncologists to contribute their experiences.”
For pharmaceutical marketers, the larger potential sample size of U.S. oncologists has immediate business value:
The oncology market grows more sophisticated each year, as pharmaceutical companies vie to stay ahead of increased competition and more rigorous approval cycles.
IntrinsiQ is the national leader in medical oncology care software and the only source for automated longitudinal data on trends in cancer drug usage. Its up-to-theminute record of more than 128,000 drug administrations provided monthly to 18,500 individual patients is unmatched.
“For pharmaceutical companies to stay ahead, they need data that’s broad, deep and accurate,” said Brent Clough, president and CEO of IntrinsiQ. “We provide insight on more than 1.5 million drug administrations each year. And we help turn that data into insights that drive business strategy – and best practices for oncologists.”
IntrinsiQ, LLC is the premier source for US oncology data and analysis. Each month, IntrinsiQ’s market leading software application, IntelliDose®, captures the treatment decisions and details from more than 550 unique physicians, for more than 18,500 unique patients, and regarding more than 128,000 drug administrations. The IntrinsiQ database is unrivaled in accuracy, detail and timeliness of information about the medical oncology care process. This database is the foundation of products and services that uniquely address the business information needs of pharmaceutical product managers, market researchers and financial analysts. For more information, please visit www.intrinsiq.com.
Brent Clough
IntrinsiQ, LLC
(781) 647-1144